---
document_datetime: 2026-02-05 15:00:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/yuflyma.html
document_name: yuflyma.html
version: success
processing_time: 0.113937
conversion_datetime: 2026-02-09 22:26:01.454228
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Yuflyma

# Yuflyma

[RSS](/en/individual-human-medicine.xml/67410)

##### Authorised

This medicine is authorised for use in the European Union

adalimumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Yuflyma](#news-on)
- [Related content](#related-content-922)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79699)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Yuflyma is a medicine that acts on the immune system (the body's natural defences) and is used to treat the following conditions:

- plaque psoriasis (a disease causing red, scaly patches on the skin);
- psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints);
- rheumatoid arthritis (a disease causing inflammation of the joints);
- polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis (both rare diseases causing inflammation in the joints);
- axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when there are clear signs of inflammation but X-ray does not show disease;
- Crohn's disease (a disease causing inflammation of the gut);
- ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);
- hidradenitis suppurativa (acne inversa), a chronic skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin;
- non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).

Yuflyma is mostly used in adults when their condition is severe, moderately severe or getting worse, or when patients cannot use other treatments. For more information on the use of Yuflyma in all conditions, including when it can be used in children, see the package leaflet or contact your doctor or pharmacist.

Yuflyma is a 'biosimilar medicine'. This means that Yuflyma is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Yuflyma is Humira. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines) .

Yuflyma contains the active substance adalimumab.

Expand section

Collapse section

## How is Yuflyma used?

Yuflyma is available in a pre-filled syringe or pen and is given as an injection under the skin, usually every 2 weeks. The dose and frequency of injections depend on the condition being treated and the dose for a child is usually calculated according to the child's weight. After training, patients or their carers may inject Yuflyma if their doctor considers it appropriate.

Yuflyma can only be obtained with a prescription and treatment must be started and supervised by a doctor who has experience in the treatment of the diseases for which Yuflyma is used. Eye specialists treating uveitis should also take advice from doctors who have experience of using adalimumab.

For more information about using Yuflyma, see the package leaflet or contact your doctor or pharmacist.

## How does Yuflyma work?

The active substance in Yuflyma, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Yuflyma is used to treat. By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.

## What benefits of Yuflyma have been shown in studies?

Laboratory studies comparing Yuflyma with Humira have shown that the active substance in Yuflyma is highly similar to that in Humira in terms of structure, purity and biological activity. Studies have also shown that giving Yuflyma produces similar levels of the active substance in the body to giving Humira.

In addition, a study involving 648 patients with moderate to severe rheumatoid arthritis has shown that Yuflyma was as effective as Humira in reducing symptoms of the disease when given with methotrexate. After 24 weeks, the proportion of patients with at least a 20% improvement in symptom score (called ACR20) was 83% (268 of 324 patients) with both medicines.

Because Yuflyma is a biosimilar medicine, the studies on effectiveness and safety of adalimumab carried out with Humira do not all need to be repeated for Yuflyma.

## What are the risks associated with Yuflyma?

For the full list of side effects and restrictions with Yuflyma, see the package leaflet.

The safety of Yuflyma has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Humira.

The most common side effects with adalimumab (which may affect more than 1 in 10 people) are infections (including in the nose, throat and sinuses), injection site reactions (redness, itching, bleeding, pain or swelling), headache and muscle and bone pain. Like other medicines of its class, Yuflyma may affect the ability of the immune system to fight off infections and cancer, and there have been some cases of serious infections and blood cancers in patients using adalimumab.

Other rare serious side effects of adalimumab (which may affect up to 1 in 1,000 people) include failure of the bone marrow to produce blood cells, disorder of the nerves, lupus and lupus-like conditions (where the immune system attacks the patient's own tissues, causing inflammation and organ damage), and Stevens-Johnson syndrome (a life-threatening reaction with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals).

Yuflyma must not be used in patients with active tuberculosis or other severe infections, or in patients with moderate to severe heart failure (an inability of the heart to pump enough blood around the body).

## Why is Yuflyma authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Yuflyma has a highly similar structure, purity and biological activity to Humira and is distributed in the body in the same way. In addition, studies in patients with rheumatoid arthritis have shown that the safety and effectiveness of Yuflyma is equivalent to that of Humira.

All these data were considered sufficient to conclude that Yuflyma will behave in the same way as Humira in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Humira, the benefits of Yuflyma outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Yuflyma?

Patients treated with Yuflyma must be given a reminder card with information on the safety of the medicine.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yuflyma have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Yuflyma are continuously monitored. Side effects reported with Yuflyma are carefully evaluated and any necessary action taken to protect patients.

## Other information about Yuflyma

Yuflyma received a marketing authorisation valid throughout the EU on 11 February 2021.

Yuflyma : EPAR - Medicine overview

Reference Number: EMA/539305/2023

English (EN) (146.39 KB - PDF)

**First published:** 26/02/2021

**Last updated:** 09/01/2024

[View](/en/documents/overview/yuflyma-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-657)

български (BG) (171.67 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/bg/documents/overview/yuflyma-epar-medicine-overview_bg.pdf)

español (ES) (146.57 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/es/documents/overview/yuflyma-epar-medicine-overview_es.pdf)

čeština (CS) (169.9 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/cs/documents/overview/yuflyma-epar-medicine-overview_cs.pdf)

dansk (DA) (145.93 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/da/documents/overview/yuflyma-epar-medicine-overview_da.pdf)

Deutsch (DE) (151.58 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/de/documents/overview/yuflyma-epar-medicine-overview_de.pdf)

eesti keel (ET) (143.49 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/et/documents/overview/yuflyma-epar-medicine-overview_et.pdf)

ελληνικά (EL) (172.41 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/el/documents/overview/yuflyma-epar-medicine-overview_el.pdf)

français (FR) (149.53 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/fr/documents/overview/yuflyma-epar-medicine-overview_fr.pdf)

hrvatski (HR) (168.07 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/hr/documents/overview/yuflyma-epar-medicine-overview_hr.pdf)

italiano (IT) (144.75 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/it/documents/overview/yuflyma-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (167 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/lv/documents/overview/yuflyma-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (169.72 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/lt/documents/overview/yuflyma-epar-medicine-overview_lt.pdf)

magyar (HU) (170.88 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/hu/documents/overview/yuflyma-epar-medicine-overview_hu.pdf)

Malti (MT) (172.58 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/mt/documents/overview/yuflyma-epar-medicine-overview_mt.pdf)

Nederlands (NL) (147.58 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/nl/documents/overview/yuflyma-epar-medicine-overview_nl.pdf)

polski (PL) (173 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/pl/documents/overview/yuflyma-epar-medicine-overview_pl.pdf)

português (PT) (147.09 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/pt/documents/overview/yuflyma-epar-medicine-overview_pt.pdf)

română (RO) (167.47 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/ro/documents/overview/yuflyma-epar-medicine-overview_ro.pdf)

slovenčina (SK) (169.87 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/sk/documents/overview/yuflyma-epar-medicine-overview_sk.pdf)

slovenščina (SL) (167.45 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/sl/documents/overview/yuflyma-epar-medicine-overview_sl.pdf)

Suomi (FI) (142.81 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/fi/documents/overview/yuflyma-epar-medicine-overview_fi.pdf)

svenska (SV) (144.55 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

09/01/2024

[View](/sv/documents/overview/yuflyma-epar-medicine-overview_sv.pdf)

Yuflyma : EPAR - Risk management plan

English (EN) (929.97 KB - PDF)

**First published:** 26/02/2021

**Last updated:** 05/02/2026

[View](/en/documents/rmp/yuflyma-epar-risk-management-plan_en.pdf)

## Product information

Yuflyma : EPAR - Product information

English (EN) (4.81 MB - PDF)

**First published:** 26/02/2021

**Last updated:** 05/02/2026

[View](/en/documents/product-information/yuflyma-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-525)

български (BG) (5.4 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/bg/documents/product-information/yuflyma-epar-product-information_bg.pdf)

español (ES) (4.54 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/es/documents/product-information/yuflyma-epar-product-information_es.pdf)

čeština (CS) (4.54 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/cs/documents/product-information/yuflyma-epar-product-information_cs.pdf)

dansk (DA) (4.16 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/da/documents/product-information/yuflyma-epar-product-information_da.pdf)

Deutsch (DE) (4.87 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/de/documents/product-information/yuflyma-epar-product-information_de.pdf)

eesti keel (ET) (4.68 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/et/documents/product-information/yuflyma-epar-product-information_et.pdf)

ελληνικά (EL) (6.01 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/el/documents/product-information/yuflyma-epar-product-information_el.pdf)

français (FR) (4.88 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/fr/documents/product-information/yuflyma-epar-product-information_fr.pdf)

hrvatski (HR) (5.14 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/hr/documents/product-information/yuflyma-epar-product-information_hr.pdf)

íslenska (IS) (4.06 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/is/documents/product-information/yuflyma-epar-product-information_is.pdf)

italiano (IT) (4.8 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/it/documents/product-information/yuflyma-epar-product-information_it.pdf)

latviešu valoda (LV) (5.34 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/lv/documents/product-information/yuflyma-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.87 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/lt/documents/product-information/yuflyma-epar-product-information_lt.pdf)

magyar (HU) (5.29 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/hu/documents/product-information/yuflyma-epar-product-information_hu.pdf)

Malti (MT) (5.38 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/mt/documents/product-information/yuflyma-epar-product-information_mt.pdf)

Nederlands (NL) (4.06 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/nl/documents/product-information/yuflyma-epar-product-information_nl.pdf)

norsk (NO) (4.11 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/no/documents/product-information/yuflyma-epar-product-information_no.pdf)

polski (PL) (5.18 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/pl/documents/product-information/yuflyma-epar-product-information_pl.pdf)

português (PT) (3.86 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/pt/documents/product-information/yuflyma-epar-product-information_pt.pdf)

română (RO) (5.01 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/ro/documents/product-information/yuflyma-epar-product-information_ro.pdf)

slovenčina (SK) (5.06 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/sk/documents/product-information/yuflyma-epar-product-information_sk.pdf)

slovenščina (SL) (5.13 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/sl/documents/product-information/yuflyma-epar-product-information_sl.pdf)

Suomi (FI) (4.58 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/fi/documents/product-information/yuflyma-epar-product-information_fi.pdf)

svenska (SV) (4.56 MB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/02/2026

[View](/sv/documents/product-information/yuflyma-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000295845 30/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Yuflyma : EPAR - All authorised presentations

English (EN) (55.4 KB - PDF)

**First published:** 26/02/2021

**Last updated:** 05/11/2024

[View](/en/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-164)

български (BG) (70.88 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/bg/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.64 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/es/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_es.pdf)

čeština (CS) (76.12 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/cs/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.28 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/da/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.63 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/de/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.98 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/et/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.46 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/el/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_el.pdf)

français (FR) (49.87 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/fr/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (91.3 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/hr/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.55 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/is/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.43 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/it/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.12 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/lv/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (73.11 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/lt/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (71.42 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/hu/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (75.85 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/mt/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.53 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/nl/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.39 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/no/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_no.pdf)

polski (PL) (74.99 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/pl/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_pl.pdf)

português (PT) (52.05 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/pt/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.53 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/ro/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.45 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/sk/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (70.21 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/sl/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.78 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/fi/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.2 KB - PDF)

**First published:**

26/02/2021

**Last updated:**

05/11/2024

[View](/sv/documents/all-authorised-presentations/yuflyma-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Yuflyma Active substance adalimumab International non-proprietary name (INN) or common name adalimumab Therapeutic area (MeSH)

- Arthritis, Rheumatoid
- Arthritis, Psoriatic
- Psoriasis
- Spondylitis, Ankylosing
- Uveitis
- Hidradenitis Suppurativa
- Colitis, Ulcerative
- Crohn Disease
- Arthritis, Juvenile Rheumatoid

Anatomical therapeutic chemical (ATC) code L04AB04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Rheumatoid arthritis**

Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

**Juvenile idiopathic arthritis** Polyarticular juvenile idiopathic arthritis Yuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.

**Enthesitis-related arthritis** Yuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).

**Axial spondyloarthritis** Ankylosing spondylitis (AS) Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

Axial spondyloarthritis without radiographic evidence of AS Yuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).

**Psoriatic arthritis** Yuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.

Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.

**Psoriasis** Yuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

**Paediatric plaque psoriasis** Yuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

**Hidradenitis suppurativa (HS** ) Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).

**Crohn's disease** Yuflyma is indicated for treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

**Paediatric Crohn's disease** Yuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.

**Ulcerative colitis** Yuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

**Paediatric ulcerative colitis** Yuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

**Uveitis** Yuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.

**Paediatric uveitis** Yuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

## Authorisation details

EMA product number EMEA/H/C/005188

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Celltrion Healthcare Hungary Kft.

1062 Budapest Váci út 1-3. WestEnd Office Building B torony Hungary

Opinion adopted 10/12/2020 Marketing authorisation issued 11/02/2021 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Yuflyma : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.51 KB - PDF)

**First published:** 27/03/2025

**Last updated:** 05/02/2026

[View](/en/documents/procedural-steps-after/yuflyma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Yuflyma : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (151.01 KB - PDF)

**First published:** 17/05/2021

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/yuflyma-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Yuflyma : EPAR - Public assessment report

Adopted

Reference Number: EMA/47907/2021

English (EN) (3.9 MB - PDF)

**First published:** 26/02/2021

[View](/en/documents/assessment-report/yuflyma-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Yuflyma

Adopted

Reference Number: EMA/CHMP/639447/2020

English (EN) (192.48 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-yuflyma_en.pdf)

#### News on Yuflyma

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Yuflyma : EPAR - Product information - tracked changes

English (EN) (7.67 MB - DOCX)

**First published:** 29/09/2025

[View](/en/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-769)

български (BG) (13.41 MB - DOCX)

**First published:**

29/09/2025

[View](/bg/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_bg.docx)

español (ES) (7 MB - DOCX)

**First published:**

29/09/2025

[View](/es/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_es.docx)

čeština (CS) (12.12 MB - DOCX)

**First published:**

29/09/2025

[View](/cs/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (10.12 MB - DOCX)

**First published:**

29/09/2025

[View](/da/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (14.66 MB - DOCX)

**First published:**

29/09/2025

[View](/de/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (8.47 MB - DOCX)

**First published:**

29/09/2025

[View](/et/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (9.1 MB - DOCX)

**First published:**

29/09/2025

[View](/el/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_el.docx)

français (FR) (10.32 MB - DOCX)

**First published:**

29/09/2025

[View](/fr/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (7.85 MB - DOCX)

**First published:**

29/09/2025

[View](/hr/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (9.39 MB - DOCX)

**First published:**

29/09/2025

[View](/is/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_is.docx)

italiano (IT) (12.77 MB - DOCX)

**First published:**

29/09/2025

[View](/it/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (13.59 MB - DOCX)

**First published:**

29/09/2025

[View](/lv/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (12.71 MB - DOCX)

**First published:**

29/09/2025

[View](/lt/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (15.15 MB - DOCX)

**First published:**

29/09/2025

[View](/hu/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (17.4 MB - DOCX)

**First published:**

29/09/2025

[View](/mt/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (11.38 MB - DOCX)

**First published:**

29/09/2025

[View](/nl/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (9.92 MB - DOCX)

**First published:**

29/09/2025

[View](/no/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_no.docx)

polski (PL) (14.24 MB - DOCX)

**First published:**

29/09/2025

[View](/pl/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_pl.docx)

português (PT) (4.09 MB - DOCX)

**First published:**

29/09/2025

[View](/pt/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_pt.docx)

română (RO) (13.72 MB - DOCX)

**First published:**

29/09/2025

[View](/ro/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (4.85 MB - DOCX)

**First published:**

29/09/2025

[View](/sk/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (12.55 MB - DOCX)

**First published:**

29/09/2025

[View](/sl/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (10.65 MB - DOCX)

**First published:**

29/09/2025

[View](/fi/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (9.93 MB - DOCX)

**First published:**

29/09/2025

[View](/sv/documents/product-information-tracked-changes/yuflyma-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 05/02/2026

## Share this page

[Back to top](#main-content)